Friday, March 27

Pregnancy and the Heart: What Every Clinician Needs to Know in 2026
Marriott Warehouse Arts District | Cypress Ballroom (2nd Floor)
6 – 9 p.m.

Join Mayo Clinic for a complimentary evening of cardiovascular obstetrics. Enjoy a dinner followed by an interactive case-based discussion where we will focus on cardiovascular disease in pregnancy, a leading cause of maternal mortality. Join us for:

• Multidisciplinary evidence-based approaches to high-risk obstetric cardiovascular conditions
• Case-driven insights applicable to real-world clinical practice
• Complimentary dinner and the opportunity to network with colleagues

This program is designed to support collaborative care and provide practical strategies applicable to clinical practice. Register today.

Speakers

Katie A. Young, MD (Course Director)
Rekha Mankad, MD (Course Director)
Demilade A. Adedinsewo, MB, ChB
Kari A. Dessner, APRN, CNP
Marissa L. Kauss, MD
David S. Majdalany, MD
Carl H. Rose, MD
Marysia S. Tweet, MD, MS
Carole A. Warnes, MD

Friday, March 27 – Evening Events

4513. Impacting Patient Outcomes in ATTR-CM Through Early Recognition and Treatment
6 p.m. – Midnight
Sponsored by BridgeBio

4514. Cracking the Code: Practical Encounters and Evolving Evidence in HF and CKD Care
6 p.m. – Midnight
Sponsored by Boehringer Ingelheim

4515. Title to be Announced
6 p.m. – Midnight
Sponsored by Medtronic

Saturday, March 28 – Morning Events

4501. Title to be Announced
5:30 – 8 a.m.
Sponsored by The Mended Hearts for Alynlyam

4503. Title to be Announced
5:30 – 8 a.m.
Sponsored by GE Healthcare

4502. Mastering the Intersection: Applying Non-Steroidal MRAs in Cardio-Kidney-Metabolic Disease
7 – 8 a.m.
Hilton Riverside, Grand Ballroom A
Sponsored by Bayer

Metabolic dysfunction drives substantial morbidity, mortality, and health burden across type 2 diabetes (T2D), chronic kidney disease (CKD), and heart failure (HF), yet screening and treatment remain suboptimal. With rising prevalence and persistent residual risk, clinicians need timely, practical education to improve early recognition and confidently apply evidence-based therapies—especially non-steroidal mineralocorticoid receptor antagonists (nsMRAs)—for these complex, interrelated conditions.

Join expert faculty for a dynamic Test-and-Teach symposium that brings real-world cardiovascular-kidney-metabolic (CKM) cases to life while clarifying when and how to use nsMRAs across heart failure with preserved ejection fraction (HFpEF), CKD in T2D, and emerging type 1 diabetes (T1D) evidence. Strengthen your diagnostic skills, treatment confidence, and shared decision-making approaches to optimize outcomes for high-risk patients.

Saturday, March 28 – Evening Events

4506. HCM Headlines Game-Changing Advances in Treatment
5:30 – 7 p.m.
Hilton Riverside, Grand Ballroom A
Sponsored by Cytokinetics

Hypertrophic cardiomyopathy (HCM) remains underrecognized, often mimicking more common cardiovascular conditions and leading to delays in diagnosis and gaps in care. Join our panel of experts for a news-style symposium to get high-impact updates on the latest advances in identifying HCM and the emerging evidence on cardiac myosin inhibition (CMI) therapy to optimize individualized treatment. Join us to stay ahead of the headline, and elevate your ability to deliver precise, patient-centered HCM care!

4504. From Bench to Bedside: RNAi Therapeutics in Cardiovascular Diseases
5:30 p.m. – Midnight
Sponsored by Alnylam Pharmaceuticals

4505. Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction
5:30 p.m. – Midnight
Sponsored by Clinical Care Options, LLC dba Decera Clinical Education. Supported by an educational grant from Novartis Pharmaceuticals Corporation.

This program will equip healthcare professionals to elevate ASCVD prevention through interactive, case-based learning focused on today's most challenging lipid-management gaps. Faculty will guide participants in integrating lipoprotein(a) testing into routine cardiovascular risk assessment, recognizing its role as an independent and under-addressed driver of ASCVD. Through brief lectures paired with interactive discussions, attendees will apply current guideline recommendations to develop individualized lipid-lowering strategies, including nonstatin and combination therapies. The session will also address clinical inertia and patient-centered barriers, empowering clinicians to implement guideline-directed care that improves real-world outcomes.

Speakers:

Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC
Medical Director
Center for Cardiovascular Analytics, Research, and Data Science (CARDS)
Providence Heart Institute
Providence Health System

Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert
Associate Professor of Research, Preventive Cardiology PA
Intermountain Advanced Lipid and Cardiovascular Prevention Clinic
Intermountain Health

Erin Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Professor of Medicine
Director of Women's Cardiovascular Health
Associate Director of Preventive Cardiology
Core Faculty, Advanced Lipid Clinic
Division of Cardiology
Johns Hopkins University School of Medicine

Pam R. Taub, MD, FACC, FASPC
Step Family Director's Endowed Chair
Director of Preventive Cardiology
Director of Step Family Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System

Sunday, March 29 – Morning Events

4508. Title to be Announced
5:30 – 8 a.m.
Sponsored by The Mended Hearts

4507. New Pathways in Antithrombotic Therapy
6:30 – 8 a.m.
Hilton Riverside, Grand Ballroom A
Sponsored by an educational grant from the Bristol Myers Squibb and Janssen Pharmaceuticals, Inc. Alliance.

Thromboembolic disease is responsible for 1 in every 4 deaths throughout the world. Though currently available anticoagulants can significantly reduce the risk of thromboembolism in patients with atrial fibrillation (AF), venous thromboembolism (VTE), stroke, and other cardiovascular conditions, they are often underutilized in eligible patients or utilized inappropriately primarily due to safety concerns, leading to suboptimal patient outcomes. Emerging evidence suggests that factor XI is a promising new target for inhibition of pathological thrombosis with minimal impairment to physiological hemostasis, paving the way toward a safer anticoagulation strategy. Through immersive patient journeys and expert commentary, this symposium will empower learners to make individualized, evidence-based decisions and be prepared for the integration of novel anticoagulants into clinical practice.

4509. Revolutionizing Recurrent AMI Care: Addressing Unmet Needs With Early Intervention Strategies
7 – 8 a.m.
Hilton Riverside, Grand Salon B (1st Floor)
Sponsored by Viatris

Every 40 seconds, someone in the United States suffers from acute myocardial infarction (AMI), requiring emergency care. The delay from symptom onset to initiation of therapy to reduce the total ischemic time after AMI has not improved in decades. Prolonged ischemic time is strongly associated with poor prognosis after AMI, due to increased myocardial damage and higher risk for death and heart failure. This prolonged time frame underscores the urgent need for strategies that can reduce ischemic time and improve patient outcomes by addressing barriers to timely intervention. In this fast-paced symposium, experts will discuss limitations in current care pathways for recurrent AMI, the rationale for pre-hospital antiplatelet therapies, and the evolving clinical landscape of early interventions.

Sunday, March 29 – Evening Events

4510. Title to be Announced
5:30 p.m. – Midnight
Sponsored by Heartflow

4511. Title to be Announced
5:30 p.m. – Midnight
Sponsored by Edwards Lifesciences

4512. Shifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidenced-Based Therapies To Optimize Patient Outcomes
6:30 – 8:30 p.m.
Sponsored by Clinical Care Options, LLC dba Decera Clinical Education. Supported by an independent medical educational grant from Boehringer Ingelheim Pharmaceuticals, Inc. and Eli Lilly and Company.

Cardiology healthcare professionals (HCPs) are crucial in the proper use of evidence-based therapies for patients with cardio-renal-metabolic (CRM) diseases. Clinical inertia continues to limit optimal care delivery for patients with CRM diseases. This program addresses hesitancy among cardiology HCPs and patients to initiate or continue guideline-directed medical therapy.

Speakers:

Stephen J. Greene MD
Associate Professor of Medicine, Division of Cardiology
Duke Clinical Research Institute
Duke University School of Medicine
Durham, NC

Ty J. Gluckman MD MHA
Medical Director, Center for Cardiovascular Analytics, Research, and Data Science
Providence Heart Institute
Providence Health System
Portland, OR